Clinical Trials

390 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03233711 2026-03-18

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

344 enrolled

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT03811015 2026-03-18

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

636 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT06498635 2026-03-18

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

306 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02954874 2026-03-17

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03055013 2026-03-17

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Phase 3 Not yet recruiting

819 enrolled 12 charts

Genitourinary

Carcinoma, Renal Cell

NCT07388524 2026-03-17

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

336 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06401330 2026-03-05

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

1,656 enrolled

Genitourinary

Stage I Mixed Cell Type Kidney Wilms Tumor

NCT05812807 2026-03-04

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

1,295 enrolled

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT05976763 2026-03-04

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

421 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

1,150 enrolled 6 charts

Dermatologic

Melanoma

NCT06647953 2026-02-24

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

110 enrolled

Pleuropulmonary blastoma

NCT06745024 2026-01-15

Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial

280 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03180268 2026-01-14

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

163 enrolled

CNS

Meningioma

NCT03803553 2025-12-23

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

400 enrolled

Gastrointestinal

Colonic Neoplasms

NCT02176967 2025-12-22

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

621 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03533582 2025-12-22

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

537 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Hepatoblastoma

NCT02201992 2025-12-19

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

166 enrolled